Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston Apr 13, 2023 11:10am
161 Views
Post# 35393005

RE:RE:RE:Looked at Q3 filing on Sedar again

RE:RE:RE:Looked at Q3 filing on Sedar again

N0taP00p ... Here's some fresh input and perspectives so you want to sound more credible and look more educated instead like posing like an uninformed in your next armchair quarterback posts.

Q1 biotech layoffs rise 87% YOY, already halfway to 2022 total

In the first quarter of 2023, 56 biopharmas laid off staff—an 87% jump over the same period in 2022, when 30 companies made cuts.


Not an obvious environment for anybody but we should get there, with high distinction of our efficacy %s keep climbing.  And it won't be because of you.  

You clearly don't have the attitude to face challenges. Whining seems to be your best "strength", part of your DNA.  That's sad!

<< Previous
Bullboard Posts
Next >>